Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

(2016) Fred Poordad et al.   HEPATOLOGY

Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C

(2016) Goki Suda et al.   JOURNAL OF GASTROENTEROLOGY

The ARRIBA concept: adequate resorption of ribavirin

(2015) Clara TMM de Kanter et al.   ANTIVIRAL THERAPY

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment

(2015) Tushar Garimella et al.   ANTIVIRAL THERAPY

Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions

(2015) Timothy Eley et al.   CLINICAL PHARMACOKINETICS

Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug–Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir

(2015) Erik Mogalian et al.   CLINICAL PHARMACOKINETICS

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

(2015) Bashar A. Aqel et al.   HEPATOLOGY

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

(2015) Varun Saxena et al.   HEPATOLOGY

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

(2015) Andrew J. Muir et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment

(2015) E. Mogalian et al.   JOURNAL OF HEPATOLOGY

P0910 : No evidence of pharmacokinetic drug–drug interaction in healthy subjects between coadministered grazoprevir (MK-5172)/elbasvir (MK-8742) and sofosbuvir

(2015) W.L. Marshall et al.   JOURNAL OF HEPATOLOGY

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment

(2015) Amit Khatri et al.   JOURNAL OF HEPATOLOGY

O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)

(2015) I.M. Jacobson et al.   JOURNAL OF HEPATOLOGY

P0790 : The effect of renal impairment on multiple-dose pharmacokinetics of the fixed-dose combination of daclatasvir/asunaprevir/beclabuvir

(2015) R. Adamczyk et al.   JOURNAL OF HEPATOLOGY

LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target

(2015) V. Saxena et al.   JOURNAL OF HEPATOLOGY

LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study

(2015) P.J. Pockros et al.   JOURNAL OF HEPATOLOGY

Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease

(2015) Bhamidimarri Kalyan Ram et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

(2015) David Roth et al.   LANCET

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

(2015) Marc Bourlière et al.   LANCET INFECTIOUS DISEASES

Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR

(2015) Hector E. Nazario et al.   LIVER INTERNATIONAL

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

(2015) Michael P. Curry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

(2015) Graham R. Foster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

(2015) Jordan J. Feld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review

(2015) Jonathan Manuel Aguirre Valadez et al.   Therapeutics and Clinical Risk Management

The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor

(2014) Timothy Eley et al.   ANTIVIRAL THERAPY

MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection

(2014) Ivan Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

(2014) Christophe Hézode et al.   GASTROENTEROLOGY

Global epidemiology and genotype distribution of the hepatitis C virus infection

(2014) Erin Gower et al.   JOURNAL OF HEPATOLOGY

P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY

(2014) J.-H. Kao et al.   JOURNAL OF HEPATOLOGY

P742 THE PHARMACOKINETICS OF GS-5816, A PAN-GENOTYPIC HCV NS5A INHIBITOR, IN HCV-UNINFECTED SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT

(2014) E. Mogalian et al.   JOURNAL OF HEPATOLOGY

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

(2014) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment

(2013) B. J. Brennan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telaprevir Twice Daily Is Noninferior to Telaprevir Every 8 Hours for Patients With Chronic Hepatitis C

(2013) Maria Buti et al.   GASTROENTEROLOGY

887 PHARMACOKINETICS OF SIMEPREVIR (TMC435) IN VOLUNTEERS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT

(2013) S. Ouwerkerk-Mahadevan et al.   JOURNAL OF HEPATOLOGY

Global control of hepatitis C: where challenge meets opportunity

(2013) David L Thomas   NATURE MEDICINE

Measuring Ribavirin Concentrations During the Earliest Stages of Antiviral Therapy for Hepatitis C

(2013) Lotte G. van Vlerken et al.   THERAPEUTIC DRUG MONITORING

Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease

(2013) Ashwani K. Singal et al.   TRANSPLANTATION

1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS

(2012) E. Lawitz et al.   JOURNAL OF HEPATOLOGY

1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977

(2012) M.T. Cornpropst et al.   JOURNAL OF HEPATOLOGY

472 PHARMACOKINETICS OF TMC435 IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT

(2011) V. Sekar et al.   JOURNAL OF HEPATOLOGY

Pharmacokinetics and dosage adjustment in patients with renal dysfunction

(2009) Roger K. Verbeeck et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

(2008) E. T. Morgan et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C

(2008) J. Morello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY